Abiopharma

🔍 Moreadith Randall (Executive)

Company: Serina Therapeutics, Inc. (SER)

Report Date: 2025-12-09

Detailed Transactions and Holdings:

• Acquired 600 shares of Common Stock at $0.06 per share (Direct)
  Date: 2025-12-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 600.00 | transaction_form_type: 4
• Sold 600 shares of Common Stock at $3.3133 per share (Direct)
  Date: 2025-12-09 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Acquired 645 shares of Common Stock at $0.06 per share (Direct)
  Date: 2025-12-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 645.00 | transaction_form_type: 4
• Sold 645 shares of Common Stock at $3.35 per share (Direct)
  Date: 2025-12-10 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4
• Sold 600 shares of Stock Option (right to buy) at $0.06 per share (Derivative)
  Date: 2025-12-09 | Code: M | Expires: 2031-05-06 | equity_swap_involved: 0 | shares_owned_after: 371,086.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 645 shares of Stock Option (right to buy) at $0.06 per share (Derivative)
  Date: 2025-12-10 | Code: M | Expires: 2031-05-06 | equity_swap_involved: 0 | shares_owned_after: 370,441.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F2: The stock options are fully vested.